Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Edgewise Therapeutics, Inc. EWTX
$8.93
-$0.55 (-6.15%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
611115750.00000000
-
week52high
14.33
-
week52low
5.41
-
Revenue
0
-
P/E TTM
-8
-
Beta
-0.18713800
-
EPS
-1.15000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Sell | Neutral | 25 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 24 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 12 мая 2022 г. |
| Goldman Sachs | Neutral | Neutral | 12 мая 2022 г. |
| RBC Capital | Outperform | 13 апр 2022 г. | |
| RBC Capital | Outperform | Outperform | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Semigran Marc | A | 300000 | 300000 | 30 дек 2022 г. |
| MOORE JOHN R | D | 122997 | 4730 | 03 окт 2022 г. |
| MOORE JOHN R | D | 3000 | 4730 | 03 окт 2022 г. |
| MOORE JOHN R | A | 7730 | 4730 | 03 окт 2022 г. |
| ORBIMED ADVISORS LLC | A | 13981952 | 484496 | 16 сент 2022 г. |
| Thompson Peter A. | A | 13981952 | 484496 | 16 сент 2022 г. |
| Novo Holdings A/S | A | 6071703 | 484496 | 14 сент 2022 г. |
| MOORE JOHN R | D | 127727 | 4730 | 06 сент 2022 г. |
| MOORE JOHN R | D | 3000 | 2351 | 06 сент 2022 г. |
| MOORE JOHN R | D | 5351 | 2379 | 06 сент 2022 г. |
Новостная лента
Edgewise Therapeutics, Inc. (EWTX) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
25 окт 2022 г. в 13:32
Edgewise Therapeutics, Inc. (EWTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Purple Innovation and Edgewise Therapeutics See Activist Investor Action
Market Watch
23 сент 2022 г. в 18:35
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study
Zacks Investment Research
13 сент 2022 г. в 18:48
Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).
6 Blue-Chip Stocks to Sell Now
InvestorPlace
18 июл 2022 г. в 11:44
This article is about 6 blue-chip stocks to sell now. The stocks are overvalued or could fall due to the recession or from a downgrade in analysts' forecasts of their earnings.
RBC Capital Says This Dystrophy Stock 'Is Worth A Look'
Benzinga
22 июн 2022 г. в 14:04
RBC Capital says Edgewise Therapeutics Inc's (NASDAQ: EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD.